EcoDrugPlus

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSSMAG00000014912
Gene Symbol: SERPINC1
1 Cross references
199 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSSMAG00000019419
Gene Symbol: LOC118303373
2 Cross references
405 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSSMAG00000033064
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSSMAG00000000603
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSSMAG00000013220
Gene Symbol: SCN10A
1 Cross references
248 Possible Orthologues:

Sodium/hydrogen Exchanger 3-Like

Ensembl ID : ENSSMAG00000001859
Gene Symbol: LOC118291615
3 Cross references
234 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSSMAG00000007537
Gene Symbol: LOC118310286
3 Cross references
236 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSSMAG00000002074
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSSMAG00000016741
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSSMAG00000011282
Gene Symbol: SLC22A6L
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSSMAG00000020292
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSSMAG00000000249
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).